Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -8.91 is 26% above its 5-year average of -12.10, near the high end of its 5-year range (-21.40–-4.60).
10.00% above its 12-month average of -9.90.
Reported quarterly EPS; no daily interpolation. Q4 FY2025 (2025-12-31): -2.60.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
EARNINGS PER SHARE (EPS)
-8.91
EARNINGS PER SHARE (EPS) AVG TTM
-9.90
EARNINGS PER SHARE (EPS) AVG 3Y
-14.45
EARNINGS PER SHARE (EPS) AVG 5Y
-12.10
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.00%
CURRENT VS 3Y AVG
+38.34%
CURRENT VS 5Y AVG
+26.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$7.19M
Earnings Per Share (EPS)
-8.91
TTM Avg
-9.90
3Y Avg
-14.45
5Y Avg
-12.10
Market Cap
$7.19M
Earnings Per Share (EPS)
-26.72
TTM Avg
-36.23
3Y Avg
-30.51
5Y Avg
-16.78
Market Cap
$7.15M
Earnings Per Share (EPS)
-10.10
TTM Avg
-11.80
3Y Avg
-53.95
5Y Avg
-54.65
Market Cap
$7.12M
Earnings Per Share (EPS)
-10.16
TTM Avg
-8.56
3Y Avg
-32.56
5Y Avg
-37.85
Market Cap
$7.31M
Earnings Per Share (EPS)
-3.48
TTM Avg
-5.74
3Y Avg
-24.14
5Y Avg
-2936.24
Market Cap
$7.07M
Earnings Per Share (EPS)
-7.38
TTM Avg
-1.62
3Y Avg
-0.82
5Y Avg
-0.82
Market Cap
$7.04M
Earnings Per Share (EPS)
-81.82
TTM Avg
-336.50
3Y Avg
-753.63
5Y Avg
-537.05
Market Cap
$7.46M
Earnings Per Share (EPS)
-68.91
TTM Avg
-299.00
3Y Avg
-268.50
5Y Avg
-367.67
Market Cap
$6.88M
Earnings Per Share (EPS)
-1.31
TTM Avg
-1.19
3Y Avg
-1.26
5Y Avg
-5.87
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.19M | -8.91 | -9.90 | -14.45 | -12.10 |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | -26.72 | -36.23 | -30.51 | -16.78 |
| Longeveron Inc. (LGVN)vs › | $7.15M | -10.10 | -11.80 | -53.95 | -54.65 |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | -10.16 | -8.56 | -32.56 | -37.85 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -3.48 | -5.74 | -24.14 | -2936.24 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -7.38 | -1.62 | -0.82 | -0.82 |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -81.82 | -336.50 | -753.63 | -537.05 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | -68.91 | -299.00 | -268.50 | -367.67 |
| Exicure, Inc. (XCUR)vs › | $6.88M | -1.31 | -1.19 | -1.26 | -5.87 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | -1.16 | -3.29 | -3.69 | -2.95 |
Trailing EPS (TTM)
$-8.91
Forward EPS (Est.)
$-6.62
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -8.80 |
| 2024-12-31 | -11.00 |
| 2023-12-31 | -16.60 |
| 2022-12-31 | -21.40 |
| 2021-12-31 | -4.60 |
| 2020-12-31 | -10.20 |
| 2019-12-31 | -4.40 |
